1352925-73-5 Usage
Uses
Used in Pharmaceutical and Bioactive Compounds Synthesis:
3-Benzyl-3-azabicyclo[3.1.1]heptan-2-one serves as a key building block in the synthesis of various pharmaceuticals and bioactive compounds. Its distinctive structure allows for the creation of a wide range of molecules with potential therapeutic applications.
Used in Drug Discovery and Development:
Due to its pharmacological properties, 3-benzyl-3-azabicyclo[3.1.1]heptan-2-one is utilized in drug discovery and development processes. Researchers investigate its potential applications in treating various diseases and conditions, leveraging its unique chemical features to design new therapeutic agents.
Used in Organic Synthesis:
In the field of organic synthesis, 3-benzyl-3-azabicyclo[3.1.1]heptan-2-one is employed as an intermediate for constructing complex organic molecules. Its versatility in forming different chemical bonds and its stability contribute to its utility in creating a diverse array of organic compounds.
Used in Medicinal Chemistry:
3-Benzyl-3-azabicyclo[3.1.1]heptan-2-one is also used in medicinal chemistry for the design and synthesis of new drugs. Its structural features make it a valuable component in the development of molecules with specific biological activities, potentially leading to the creation of novel therapeutic agents.
Check Digit Verification of cas no
The CAS Registry Mumber 1352925-73-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,5,2,9,2 and 5 respectively; the second part has 2 digits, 7 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1352925-73:
(9*1)+(8*3)+(7*5)+(6*2)+(5*9)+(4*2)+(3*5)+(2*7)+(1*3)=165
165 % 10 = 5
So 1352925-73-5 is a valid CAS Registry Number.
1352925-73-5Relevant articles and documents
ARYL, HETEROARY, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS
-
Page/Page column 453; 455, (2018/09/21)
Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, and Formula V, or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.
ANGIOTENSIN-(1-7) ANALOGS AND METHODS RELATING THERETO
-
Paragraph 00143; 0147, (2017/07/06)
Angiotensin (1-7) analogs are provided. The analogs contain one or more substitutions with non-natural amino acid cis-3-(aminomethyl)cyclobutanecarboxylic acid (ACCA). Also provided are methods of making such analogs and methods for using such analogs as
Synthesis of a conformationally constrained δ-amino acid building block
O'Reilly, Elaine,Pes, Lara,Ortin, Yannick,Mueller-Bunz, Helge,Paradisi, Francesca
, p. 511 - 518 (2013/07/27)
Conformationally restricted amino acids are important components in peptidomimetics and drug design. Herein, we describe the synthesis of a novel, non-proteinogenic constrained delta amino acid containing a cyclobutane ring, cis-3(aminomethyl)cyclobutane
